Narayana Hrudayalaya: Hospital Stock Jumps 57% on Strong Q2 Results, UK Acquisition Boosts Growth Prospects

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Narayana Hrudayalaya: Hospital Stock Jumps 57% on Strong Q2 Results, UK Acquisition Boosts Growth Prospects
Overview

Narayana Hrudayalaya's stock has surged 57% year-to-date, with a recent 14% jump driven by strong September quarter results and a significant acquisition of UK's Practice Plus Group Hospitals for GBP 183 million. The company's overseas presence, particularly in the Cayman Islands contributing over 25% of Q2 revenue, sets it apart. Despite trading at a P/E discount to peers, its international operations and integration of the UK acquisition are key for future gains.

Narayana Hrudayalaya's stock has seen remarkable growth, advancing 57% in calendar 2025 and experiencing a 14% surge in the last three trading sessions, following positive September quarter results announced on November 14. This rally was accompanied by a significant increase in trading volumes. The company clarified to the BSE that there is no undisclosed price-sensitive information driving this movement, attributing it to market dynamics.

Narayana Hrudayalaya is now the fourth-largest hospital stock by market capitalization in India. Its unique differentiator among the top three larger peers (Max Healthcare Institute, Apollo Hospitals Enterprise, and Fortis Healthcare) is its substantial international presence.

The company's facilities in the Cayman Islands, located in the Western Caribbean, were a significant contributor, accounting for over 25% of total revenue in the second quarter of FY26.

On November 6, Narayana Hrudayalaya completed the acquisition of Practice Plus Group Hospitals in the UK for an enterprise value of GBP 183 million. The deal will be financed by GBP 40 million in equity from its Cayman operations and the rest through debt. This acquisition is considered reasonably valued at an EV/EBITDA of approximately 12x, based on Practice Plus's estimated GBP 250 million revenue and GBP 20 million adjusted Ebitda for the year ending September. However, the market's initial reaction to this acquisition was muted.

Despite the recent rally, Narayana Hrudayalaya trades at a P/E ratio of 35x based on FY27 estimates, which is a discount compared to its larger Indian peers trading in the 45-50x range. The complexity of its Cayman Islands operations, including ongoing losses (though negligible at $0.3 million in Q2) and challenges in its health insurance segment, might contribute to this lower valuation. The Cayman hospitals, despite a strong EBITDA margin of 44% in Q2 (20 percentage points higher than Indian operations), are yet to achieve overall positive EBITDA due to these insurance-related losses.

While the international segment faces complexities, Narayana's Indian operations also present areas for improvement. Its EBITDA margin in Q2 was 24%, comparable to Apollo Hospitals. However, its average revenue per in-patient was ₹1.49 lakh, lower than Apollo's ₹1.73 lakh, resulting in a lower Ebitda per patient (₹35,760 for Narayana versus ₹41,520 for Apollo).

Impact:
The recent stock surge and the strategic UK acquisition are positive developments for Narayana Hrudayalaya. The company's ability to integrate the UK acquisition successfully and improve the profitability of its Cayman Islands health insurance business are crucial for sustained growth. Maintaining strong performance in its core Indian operations, especially in optimizing average revenue per patient, will also be key. The stock's current discount valuation suggests potential upside if these operational challenges are effectively addressed.
Rating: 7/10

Difficult Terms:

  • Market Capitalization: The total value of a company's outstanding shares of stock. It's calculated by multiplying the total number of shares by the current market price of one share.
  • Ebitda: Earnings Before Interest, Taxes, Depreciation, and Amortization. It's a measure of a company's operating performance, excluding the impact of financing, accounting decisions, and tax environments.
  • Enterprise Value (EV): A measure of a company's total value, often used in acquisitions. It includes the market capitalization of equity, plus debt, minus cash and cash equivalents.
  • EV/EBITDA: A valuation ratio used to determine the value of a company. It's calculated by dividing the enterprise value by the earnings before interest, taxes, depreciation, and amortization. A lower ratio generally suggests a company is undervalued.
  • P/E (Price-to-Earnings) Ratio: A valuation ratio that compares a company's current share price to its earnings per share. It indicates how much investors are willing to pay for each dollar of earnings.
  • FY26/FY27: Fiscal Year 2026/2027, referring to the 12-month accounting period used by the company.
  • GBP: Great British Pound, the currency of the United Kingdom.
  • BSE: Bombay Stock Exchange, one of the major stock exchanges in India.
  • NSE: National Stock Exchange, another major stock exchange in India.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.